Another approach to unblock the anti-tumor immune response was based on the release of tumor growth factor (TGF)-α-inhibitors combined with high doses of interleukin (IL)-2 [70], loaded in liposomal polymeric gels (nanolipogels), whereas methacrylate-conjugated β-cyclodextrins were inserted inside the liposome, in order to deliver small hydrophobic molecular inhibitors and water-soluble cytokines into the tumor microenvironment. The gene discussed is IL2; the disease is neoplasm.